Citation

Saisyo A, Takasago M, Wakabayashi K, Akiyama M, Kouda K, Takasaki A, Matsunaga K, Ishida H, Kitahara T. Yakugaku Zasshi 2021; 141(7): 971-978.

Vernacular Title

転倒転落予防を目的とした不眠時指示薬標準化における薬剤経済学的評価

Copyright

(Copyright © 2021, Pharmaceutical Society of Japan)

DOI

10.1248/yakushi.21-00020

PMID

unavailable

Abstract

To reduce the number of falls caused by hypnotic agents, the standardization of insomnia treatment was carried out at Yamaguchi University Hospital from April 2019. There were concerns that medical costs would increase due to the selected medicines-suvorexant and eszopiclone-being more expensive than conventional benzodiazepines. In this study, the standardization of insomnia treatment was evaluated by pharmacoeconomics. The costs of the hypnotic agents was considered, as was the cost of examination/treatment following falls. Effectiveness was evaluated as the incidence of falls within 24 hours of taking hypnotic agents. This analysis took the public healthcare payer's perspective. Propensity score matching based on patient background, showed that, per hospitalization the medicine costs of the recommended group increased by 1,020 yen, however, the examination/treatment costs following falls decreased by 487 yen when compared with the non-recommended group. Overall, the recommended group incurred costs of 533 yen more per hospitalization for patients prescribed hypnotic agents compared to the non-recommended group, but the incidence of falls for the recommended group was significantly lower than that in the non-recommended group (1.9% vs. 6.3%; p<0.01). These results suggest that in order to prevent the incidence of falls by 1 case, it is necessary to increase costs by 12,086 yen which is the subthreshold cost for switching to the recommended medicine as standardization. The selection of recommended medicines may be a cost-effectiveness option compared with non-recommended medicines.

Language: ja

Keywords

cost-effectiveness; insomnia treatment; medical cost; medical safety; pharmacoeconomics